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Abstract Mindfulness-based interventions (MBIs) are being
increasingly applied in a variety of settings. A growing body
of evidence to support the effectiveness of these interventions
exists and there are a few published cost-effectiveness studies.
With limited resources available within public sectors (health
care, social care, and education), it is necessary to build in
concurrent economic evaluations alongside trials in order to
inform service commissioning and policy. If future research
studies are well-designed, they have strong potential to inves-
tigate the economic impact of MBIs. The particular challenge
to the health economist is how best to capture the ways that
MBIs help people adjust to or build resilience to difficult life
circumstances, and to disseminate effectively to enable policy
makers to judge the value of the contribution that MBIs can
make within the context of the limited resourcing of public
services. In anticipation of more research worldwide evaluat-
ing MBIs in various settings, this article suggests ten health
economics methodological design questions that researchers
maywant to consider prior to conductingMBI research. These
questions draw on both published standards of good method-
ological practice in economic evaluation of medical interven-
tions, and on the authors’ knowledge and experience of
mindfulness-based practice. We argue that it is helpful to view
MBIs as both complex interventions and as public health
prevention initiatives. Our suggestions for well-designed eco-
nomic evaluations ofMBIs in health and other settings, mirror
current thinking on the challenges and opportunities of public
health economics.
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Introduction
Mindfulness-based interventions (MBIs) are being increasing-
ly applied in a variety of settings. Typically anMBI is a group-
based, 8-week programme consisting of a series of mindful-
ness meditation practices led by a trained ‘mindfulness-based
teacher’. Internationally, the most renowned interventions are
mindfulness-based stress reduction (MBSR; Kabat-Zinn
1990) and mindfulness-based cognitive therapy (MBCT;
Segal et al. 2002). Published evidence on the effectiveness
of these and other MBIs has increased over the last 15 years
(Cullen 2011; Williams and Kabat-Zinn 2011). MBCT has
strong evidence of effectiveness in reducing relapse in recur-
rent depression (Piet and Hougard 2011) and is recommended
as a priority treatment for people with recurrent depression by
the National Institute for Health and Care Excellence in the
UK (NICE 2004; 2009). MBCTalso has growing evidence of
effectiveness in other areas including anxiety (Evans et al.
2008), insomnia (Heidenreich et al. 2006) and bipolar disorder
(Williams et al. 2008a). MBSR has demonstrated effective-
ness in a range of physical and mental health conditions and
with a range of population groups (see Bohlmeijer et al. 2010;
Chiesa and Serretti 2009; and Grossman et al. 2004 for
reviews). Increasingly, programmes are being developed from
MBSR and MBCT to promote resilience in general healthy
populations in schools (e.g. Kuyken et al. 2013), for parents
(e.g. Bailie et al. 2012) and in workplaces (e.g. Chaskalson
2011).
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Early proponents of MBIs argued it to be a ‘cost-effec-
tive’ alternative to one-to-one psychological therapy or in
the case of management of depression, pharmacological
intervention (Segal et al. 2002; Teasdale et al. 2000). This
was a logical hypothesis, due to MBIs being routinely
offered in the UK and USA as group-based interventions
to between 8 and 30 participants. However, the cost-
effectiveness of an intervention can only be evaluated in
relation to an alternative intervention of a lower cost and/or
greater effectiveness (Brazier et al. 2007; Drummond et al.
2005). For example, an approach should not automatically
be considered cost-effective because it is delivered in large
groups at low average cost per participant. Any effect may
be small or short-lived. Robust health economics research
is necessary to establish cost-effectiveness of any
interventions.
Worldwide, mindfulness research is at a point of rapid
expansion and application (Williams and Kabat-Zinn 2011),
and there has been a call for more health economics research
(Edwards and Bryning 2013; Kabat-Zinn 2013). This article
suggests ten methodological design questions that those re-
searchers responsible for the design of the health economics
component of MBI trials could usefully consider. Health
economists have been charged with being ‘dispassionate and
unbiased’ (Culyer 2012), but also we argue, need to be fully
informed in appropriate research design and knowledgeable
about the intervention being evaluated, and specific context in
which it is being evaluated. We argue that this is very much
the case inMBI research.Well-designed economic evaluation,
alongside future trials, offer the potential for generalisable,
unbiased, and detailed information about the potential costs
and benefits of MBIs and are more likely to usefully inform
commissioning of health care, social care, education and well-
being policies by governments and other regulatory bodies.
We propose that the economic evaluation of MBIs (even in
a clinical setting) benefits from perspectives drawn from re-
search on public health interventions because the methodo-
logical challenges in both contexts are similar. It is challenging
to capture the range of effects of public health interventions
because they are often about trying to modify individuals’
behaviours and as such are sensitive to the setting in which
interventions take place. These settings are often synergistic
with other socio-economic considerations and causality is
complex and difficult to define (Kelly et al. 2005).
Furthermore, MBIs are increasingly being offered to healthy
populations as well-being, resilience-building strategies.
These are not new methodological considerations, but they
are presented here with specific consideration of their appli-
cation to the evaluation of MBIs. The questions are based on a
well-known checklist of characteristics of good economic
evaluations (Drummond et al. 2005). They are further in-
formed by a checklist for health economics papers for publi-
cation in the British Medical Journal (BMJ 1996).
The ten methodological design questions are as follows:
1. What is the specific research question being asked about
the MBI under evaluation?
We suggest researchers formalise their health eco-
nomics research question in terms of “How cost-
effective is the MBI, for people with ‘x’, in the setting
‘y’, as compared with ‘z’ as usual practice”. An inter-
vention cannot be cost-effective if it is not first clinically
effective. We acknowledge that in stating this we are
operating within the ‘medical model’ paradigm of
Evidence-Based Medicine first proposed by Archie
Cochrane (1972). This medical model relates survival
and health-related quality of life more to medical inter-
ventions received, than to the socio-economic circum-
stances in which someone lives or psychosocial influ-
ences on health-related quality of life. His contemporary
and a founding father of British health economics, Alan
Williams, argued that it was unethical to devote scarce
health (or social care) resources towards interventions
that deliver very low benefits per currency unit (e.g. £, $
or €) spent, when those same resources have an oppor-
tunity cost (Williams 1974). This opportunity cost is the
value of resources in their next best use that could have
been devoted to the delivery of another potentially more
effective intervention, for the same group of individuals
or for other individuals, in another setting. In consider-
ation of this research question, we introduce concepts of
efficiency (getting the most from available resources),
equity (fairness in access to treatment), moral consider-
ations (ethics) and the central concept in health econom-
ics of opportunity cost (the forfeit of benefits in their
next best use). It is this final concept that distinguishes
health economists from accountants or financial plan-
ners. We consider costs in their fullest sense of what we
forgo in choosing one use of scarce resources over
another. In mostWestern societies, health care and social
care systems are funded through tax or insurance, and
the central or collective pot or budget is limited. Even in
the USA which spends more on health care per capita
and more on health care as percentage of its GDP
(17.9 % in 2011) than any other nation (OECD 2011;
WHO 2013), resources are limited to what individuals,
employers and the government are prepared to devote to
health care over and above other uses such as education,
housing, the environment and defence.
MBIs can be considered complex interventions, as
defined by the Medical Research Council in the UK
(MRC 2008). They have many inter-related compo-
nents, which may individually or synergistically account
for benefits observed in research (e.g. curriculum, group
format, characteristics of therapist/teacher, fidelity of
programme delivery). Mindfulness itself as a construct
Mindfulness (2015) 6:490–500 491
is difficult to define (Grossman 2008; Grossman and Van
Dam 2011), and it is challenging for researchers wishing
to distil out specific mechanisms of effectiveness and
cost-effectiveness. The MRC in the UK has published a
guide to the evaluation of complex interventions which
is a useful resource to those designing feasibility and/or
full trials of MBIs (MRC 2008). This guide outlines the
need to clearly ‘define’ a complex intervention, and to
this end the MBI needs to be specifically described and
documented (e.g. with a manual) to allow for compari-
sons with a control condition and to assess factors such
as intervention fidelity and adherence (Chiesa et al.
2011). The research question should define the interven-
tion, the population and the setting for the purpose of
evaluating cost-effectiveness before introducing the al-
ternative with which it will be compared
2. With what alternative intervention or situation is the
MBI to be compared?
Randomised controlled trials (RCTs) are considered
to be the gold standard within which to assess effective-
ness and cost-effectiveness (Kendall 2003). There are
many different designs of trials and not all studies of
MBIs will be in trial settings. However, in order for
evidence of the effectiveness of anMBI to be considered
on an equal plane by the medical and clinical profes-
sions, RCTs are necessary, with opportunities to build a
concurrent economic evaluation within such a trial
(Ramsey et al. 2001).
Where possible, MBI research should be within a
RCT setting. However in many settings, MBIs are being
delivered ahead of the evidence and without routine
rigorous evaluation (Bishop 2002) and thus we recog-
nise that in these cases this research should adopt a
pragmatic approach that embraces the real-world nature
of the delivery and uptake of MBIs (Edwards et al.
2008). Pragmatic trials are conducted in the community,
in full knowledge that the setting and the outside world is
likely to impact on trial outcomes, but that with an
appropriate sample size and randomisation will be able
to demonstrate a difference in effect between the inter-
vention being studied and the control condition
(Hennekens and Buring 1987).
The control condition needs to be a clinically relevant
alternative or, as is conventional, reflect ‘usual practice’,
which sometimes canmean no active treatment. In a trial of
the management of relapse of depression, Kuyken et al.
(2008) compared MBCT plus maintenance anti-
depressants (mADM) with mADM alone. This trial was
designed to reflect wide spread ‘usual care’ and acknowl-
edgedMBCTas a component of care rather than a straight-
forward alternative to pharmacological management.
In the evaluation of psychosocial interventions, espe-
cially group-based interventions, which contain an element
of ‘socialisation’, there may be some beneficial effect of
just meeting (Karasu 1986), and factors such as this be
considered in documenting, describing and standardising
the control condition in a trial of a MBI. A number of
studies have used active control groups within the trial
design of MBI evaluation (Grossman et al. 2007; Zautra
et al. 2008). In a protocol of a trial, which aims to dismantle
the various components of MBI to explain the mechanism
of an effect, the active control condition, Cognitive Psycho
Education was described and was designed to include all
components of MBCT except mindfulness meditation
practice (Williams et al. 2010). This trial aims to establish
whether MBCT is effective in preventing relapse into
depression for people who become suicidal when de-
pressed. It is as important to collect not only costs of the
intervention arm of a trial but also costs of the control arm,
to allow for calculation of an incremental cost-effectiveness
ratio (ICER).
3. How is effectiveness to be measured, and what is an
important change on such measures?
As in the evaluation of many clinical interventions,
the primary outcome measure needs to be selected and
there is a need to consider what constitutes a ‘clinically
important or significant’ change on the chosen outcome
measures. It may be that mindfulness training cannot
change the prognosis of a disease such as cancer, but
instead provides psychological support for patients deal-
ing with diagnosis, treatment and the overall experience
of cancer (Shennan et al. 2011). The outcome measure to
determine clinical effectiveness therefore needs to reflect
the area of expected change.
To date, the most compelling evidence for MBI has
been with the management of recurrent depression.
There is evidence for reduction in rates of depression
relapse (Piet and Hougaard 2011). Kuyken et al. (2010a)
outlines the mechanism by which MBCT achieves this
preventative effect through changing the participants’
relationship to the experience of depression. Rather than
fighting to prevent a depression relapse, participants
develop a compassionate and interested relationship
with the negative thoughts and emotions that can pre-
cipitate a depression episode. This radical shift in atti-
tude and approach creates a range of other well-being-
enhancing effects beyond protection from depression.
Researchers are increasingly working to capture the
diversity of effects both through process evaluation in-
tegrated within RCTs (e.g. Williams et al. 2010) and
through qualitative evaluations which can capture the
subtleties of an approach (e.g. Allen et al. 2009).
For comparison across studies, it is useful to choose
commonly used questionnaires such as, in the case of the
management of depression, the Hospital Anxiety and
Depression Scale (Zigmond and Snaith 1983). This
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supports service commissioners reviewing evidence to
interpret the relative benefit of achieving an improve-
ment on the chosen outcome measure. While using the
same measures as those used in other studies aids com-
parability, it also has the disadvantage of narrowing the
range of outcomes that are being evaluated and valued.
Researchers therefore need to also include measures
which capture the particular shift in relationship to ex-
perience that is the core focus of mindfulness-based
training (Baer et al. 2011). These are increasingly being
included in large trials (e.g. Kuyken et al. 2010b;
Williams et al. 2010) using measures of mindfulness
(Five Factor Mindfulness Questionnaire; Baer et al.
2006), self-compassion (Self-Compassion Scale; Neff
2003), rumination (Ruminative Responses Subscale of
the Response Styles Questionnaire; Treynor et al. 2003),
dysfunctional attitudes (Dysfunctional Attitudes Scale;
Oliver and Baumgart 1985) and acceptance (Acceptance
and Action Questionnaire; Hayes et al. 2004).
The early trials of MBIs were very small (Grossman
et al. 2004) and underpowered (Baer 2003). The power
of a trial is the extent to which we are able to detect a
‘real’ difference between the intervention and control
condition, and not just a difference that might come
about as a result of random difference in the population
(Altman 1990). Powering is also important to trials of
MBI because trials will often by their nature be what are
called ‘cluster randomised trials’ with each group of
participants constituting a cluster as randomisation takes
place at group level rather than individual level, perhaps
with a waiting list control (Williams et al. 2008b). The
dynamics of delivering an intervention in a group con-
text need to be acknowledged when planning powering.
The researcher must consider whether one MBI group is
the same as another, with a different teacher, a different
room and held at a different time of day. This will
determine the number of study participants necessary
to detect a true difference in outcomes of interest be-
tween arms of the trial. Powering is important to eco-
nomic evaluation in that we are concerned with joint
distributions of costs and effects for each participant in a
trial. It is well accepted in health economics that cost
data is skewed to the right (Briggs and Gray 1998). This
is due to the fact that in any sample of patients or
individuals the majority of observations are likely to be
low in cost; however, characteristically there will be a
few individuals who are very high consumers of health
and social care. Ideally, a robust economic evaluation
needs to be based on an even larger sample size than that
needed to show clinical power (Briggs and Gray 1998).
This rarely ever happens in clinical trials of any inter-
vention. Sample size is in practise determined by clinical
outcomes and limitations to the research design due to
ethical considerations and research funding opportuni-
ties. It is the task of the health economist within a multi-
disciplinary trial team, to simultaneously bring attention
to the accurate measurement of costs and to the appro-
priate measurement of outcomes or benefit.
4. Which economic analysis method is most appropriate
and from who’s perspective is the MBI evaluation being
conducted?
Traditionally, health economists have distinguished be-
tween several methods of analysis. Drummond et al.
(2005) outlines these as cost–benefit (which measures
costs and benefits in monetary terms), cost-effectiveness
(which measures outcomes in some appropriate natural
unit), cost-utility (which measures outcomes in some uni-
versal measure of health gain, e.g. the quality adjusted life
year QALY) and cost-consequence analysis (that com-
pares costs with a full range of disaggregated outcomes).
In order to determine the method of economic evalua-
tion that is most appropriate and the range of benefits and
costs to be collected, it is necessary to identify fromwhose
perspective costs and benefits are being evaluated. As
MBIs are increasingly being delivered in non-clinical
settings such as schools and workplaces, there is an in-
creasing imperative to move away from the ‘medical
model’ paradigm (which in the UK would traditionally
involve an NHS perspective in economic analysis, with a
limited range of costs and benefits collected relevant to the
NHS) and move towards a broader public sector multi-
agency perspective (Edwards et al. 2008). This wider
perspective allows for greater recognition of the need to
collect a diverse range of costs and benefits across differ-
ent sectors.
Cost-effectiveness analysis usually requires choice of a
single primary end point of a clinical trial as its measure of
effect (e.g. relapse rate in the management of depression).
Cost-utility analysis requires a preference-based measure
of health-related quality of life and it is conventional to use
a generic, non-disease-specific measure to allow for cost
per Quality Adjusted Life Year (QALY) estimates. The
QALY is an index of the additional years of life gained
from a medical or other intervention, adjusted in some
way to reflect health-related quality of life (Robinson
1993).
Cost–benefit analysis, closest to a welfarist approach,
demands that we measure all costs and benefits in mone-
tary terms from a societal perspective. Historically, this has
infrequently been used in health economics as it is difficult
to express health benefits in monetary terms. Though the
few trials with concurrent economic evaluations have
adopted a cost-utility or cost-effectiveness approach in a
clinical setting (Kuyken et al. 2008; van Ravesteijn et al.
2013), cost–benefit analysis may be the answer for cap-
turing the benefits of MBIs in non-health care settings
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such as schools and workplaces. In the case of researchers
interested in measuring the costs and benefits of mindful-
ness training in education or in the workplace, capturing
the financial impact of improving educational standards or
reducing absenteeism may be an effective way of measur-
ing benefits. In addition to cost–benefit analysis, cost-
consequence analysis has been recommended by those
tackling the methodological challenges of public health
interventions, as a way of capturing a full range of bene-
fits, to the individual, family, setting, school or workplace
and wider society (Kelly et al. 2005; Weatherly et al.
2009). Weatherly et al. (2009) describes the need to con-
sider spill over effects, referred to by economists as ‘ex-
ternalities’. For example, a parent who is coping better
with depression through MBCT may be a more effective
parent and in turn benefits may be observed in their
children’s behaviour. The education sector may therefore
receive some of the benefit of a public health intervention
delivered by the health sector. It is in considering this that
well-being becomes the concern of all government sectors
and supports a shift from a medical model paradigm of
health to an integrated ‘whole systems’ perspective. It may
be that cost-consequence analysis is also the most appro-
priate design for an economic evaluation of an MBI.
However, it is important to note that cost-consequence
analysis does not allow for a simple comparisonwith other
interventions as is possible with cost-per-QALYestimates
and may not be appropriate when a clear decision rule is
required (e.g. in health care). In principle, a trial of MBI in
a setting or patient group where generic measures have
been shown to be sensitive, e.g. management of depres-
sion (Sapin et al. 2004; Sobocki et al. 2007), and where a
threshold is relevant for a funding decision as in the case of
NICE in the UK (NICE 2008, 2013), a cost-utility ap-
proach may be more appropriate. A cost-utility analysis or
cost-effectiveness analysis embedded in a wider cost-
consequence analysis may meet commissioners need to
inform a decision rule, whilst acknowledging the wider
range of outcomes from a MBI.
5. How are costs of a MBI to be measured? And what is the
range of costs to be considered?
Micro-costing is the bottom-up construction of the
costs of a programme, treatment or intervention. Micro-
costing can involve careful specification of training
costs, staffing costs, venue overheads, materials and staff
travel, where appropriate. Micro-costing techniques
have been used effectively in similar group-based inter-
ventions such as group parenting programmes (Charles
et al. 2013) and are appropriate in an MBI context.
Micro-costing is currently being used to determine the
full costs of delivering MBIs in different settings, for
example in supporting patients receiving treatment for
cancer (Edwards and Bryning 2013).
Costing the delivery of an MBI may involve costing
training of the teacher (and these costs can be annuitised
over an appropriate period, e.g. 3–5 years, when the
teacher might be expected to continue teaching); running
costs, including ongoing supervision of teachers and
attendance on continuing professional development
training; room hire; overheads; materials such as books
and CDs for home practice; and administrative support.
Many teachers may subsidise the cost of delivering an
MBI through personally incurring the costs of ongoing
training and supervision, which may be viewed as per-
sonal development and deepening of their personal
mindfulness practice (Edwards and Bryning 2013). On
the basis that teachers’ time does have an alternative use,
these costs should be calculated and included in the
economic evaluation. This principle applies to such
things as room hire, which may appear to be ‘free’ (for
example a bookable room in a hospital, school or work-
place), and it is necessary that their market costs are
included either in the base case analysis or in sensitivity
analysis to illustrate how costs of running an MBI vary
under different assumptions, for example, about rates
paid to teachers or the number of teachers in each group.
According to the principles of economic evaluation,
all resources with alternative uses within the chosen
perspective need to be measured and valued. Where
MBIs are being delivered within a health and/or social
care setting as well as identifying the costs of delivery, it
is necessary to capture the impact of service use by
individuals following an intervention. It is important to
assess whether MBIs actually lead to any increase in
appropriate service use (through information and contact
gained or recognition and acceptance of problems), sub-
stitution or reduction of service use, or a reduction in
reliance on services (such as the family doctor).
The DIRUM database (www.dirum.org) provides a
repository of resource or service use instruments
appropriate for different clinical and non-clinical settings
(Ridyard and Hughes 2012). Capturing resource use and
associated costs enables health economists to draw con-
clusions about the impact of MBIs on demands on
traditional health and social care services. These broader
societal findings could be important to those wanting to
make a case for the funding of MBIs in future and
potential integration into primary care, school or
workplace.
6. How should benefits of a MBI be measured for an
economic evaluation?
With respect to MBIs, the challenge facing health
economists relates, firstly, to capturing the benefits of
helping people accept or adjust to difficult life circum-
stances and promote resilience and, secondly, to relating
these benefits to limited resources in health and other
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public services. A cost-utility approach requires use of a
generic preference-based utility measure which con-
siders both impact on life expectancy and health-
related quality of life.
MBIs used to help people with severe depression and
suicidal thoughts may contribute to improving life ex-
pectancy across a trial population (Williams et al. 2006).
MBIs may improve health-related quality of life across
existing life expectancy in many different settings and
for a range of health conditions or life circumstances.
In the UK, the National Institute of Health and Care
Excellence supports the use of the EQ-5D (EuroQol
Group 1990) in health economic evaluations of interven-
tions and health technologies (NICE 2013). EQ-5D is a
validated generic, health-related, preference-based mea-
sure comprising five domains: mobility, self-care, usual
activities, pain and discomfort, anxiety and depression.
Each domain has three levels (no problems,
some/moderate problems and extreme problems). The
EQ-5D scoring system defines 243 (35) possible health
states with two additional states (dead and unconscious),
where death has a value of 0 and best imaginable health
has a value of 1. The questions are complemented by a
thermometer style, visual analogue scale, with 0
representing worst imaginable health and 100
representing best imaginable health, on which respon-
dents are asked to indicate their current health state. EQ-
5D has the benefit of being short, clear and quick to
complete. The more recent introduction of a five-level
version of the EQ-5D which includes the addition of
slight and severe problems to each domain (EQ-5D-5L;
Herdman et al. 2011) may deliver improved perfor-
mance while still retaining the benefit of brevity,
consisting of just five questions (Scalone et al. 2012).
As the number of economic evaluations of MBIs in-
creases, it will be interesting to see whether researchers
choose to include the EQ-5D-3L or EQ-5D-5L, and
whether this generic instrument proves sufficiently sen-
sitive to pick up the change in approach and attitude to
life that people undertaking mindfulness-based training
may experience. The EQ-5D has been successfully used
in trials of major depression (Sapin et al. 2004; Sobocki
et al. 2007). For example, the question “I can undertake
my usual activities” may at first appear to be directed
purely at the physical functioning of the individual and
does not discern how the individual is relating to their
functioning; however, it is important to note that our
psychological functioning may also influence our ability
to undertake these usual activities. While mindfulness-
based training may not directly influence functional
capacity to undertake usual activities, it is likely to affect
the level of ease with which the individual lives within
their current capacities (Kuyken et al. 2010a). An
individual who is at ease is more likely to be able to
seek and accept appropriate levels of support and less
likely to suffer from psychological distress in relation to
their functional capacity (Kuyken et al. 2010a).
We suggest that those designing an economic evalu-
ation of an MBI do include EQ-5D or another generic
alternative such as the SF-6D (Brazier et al. 2002) or
HUI (Horsman et al. 2003) to allow comparability with
clinical trials of other relevant psychological interven-
tions or in the case of depression, pharmacological in-
terventions (Brazier et al. 2007). Another emerging op-
tion is that of the ICECAPmeasures (Grewal et al. 2006;
Al-Janabi et al. 2012). The ICECAP-O, developed for
older adults, adopts a capabilities approach and is
intended to be a more encompassing quality of life
measure than the QALY (Coast 2004). There are five
domains: attachment, security, role, enjoyment and in-
dependence and four levels of capability (ranging from a
lot to none; Grewal et al. 2006). The development of the
ICECAP-A for adults again adopts a capabilities ap-
proach however is suitable for use with younger popu-
lations (Al-Janabi et al. 2012). The ICECAP-A aims to
measure factors relevant to an adult population rather
than older adults and identifies five domains: stability,
attachment, autonomy, achievement, and enjoyment and
four levels of capability (Al-Janabi et al. 2012).
Randomised trials are needed to establish whether the
conventional research instruments such as EQ-5D and
SF-6D are sufficiently sensitive to reflect such potential
benefits. In a trial of MBCT for medically unexplained
symptoms conducted in the Netherlands, the resultant
QALY gains were very small leading to an ICER of Euro
57,000 per QALY (van Ravesteijn et al. 2013). This is
significantly above the threshold of what society feels is
an appropriate investment to gain a QALY, as
operationalised by decision making bodies such as
NICE in the UK (NICE 2013). Further methodological
research is needed to compare QALY gains using EQ-
5D or SF-6D with disease-specific measures which are
relevant to the context in which the MBI is being deliv-
ered (Brazier et al. 2010). At this stage of health eco-
nomics research in the field of evaluation of mindfulness
interventions, we encourage the inclusion of generic-,
clinical- and intervention-specific outcome measures
where possible to allow for methodological enquiry.
7. Are the study results sensitive to changes to our
assumptions?
Sensitivity analysis is used in economic evaluation to
allow the researcher to vary the base case analysis to
explore how sensitive results are to changes in key
parameters, e.g. in a health care setting: length of hospi-
tal stay, grade of staff or dose of a drug (Drummond et al.
2005). A key issue in economic evaluation of group-
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based psychological therapies is dose. If people do not
attend all classes or a defined number of classes (as
outlined in the trial protocol), they do not get a ‘sufficient
dose’, and this may affect both the average cost of an
intervention, and potentially outcomes. The challenge
for the health economist is to define the ‘base case’ for
analysis. In the case of MBIs, these are the assumptions
underpinning the main analysis, for example, the num-
ber of individuals attending a class and the number of
classes constituting a MBI programme. Health econo-
mists have developed a range of more sophisticated
probabilistic sensitivity analysis techniques which aim
to further address uncertainty, going beyond using mean
values for key parameters such as costs, clinical out-
comes and utility values, and instead use the full distri-
bution of these parameters to estimate uncertainty
(Brazier et al. 2007).
Concerns about generalisability from a trial setting
lead us to consider whether the setting and context of a
trial determine its findings and extent to which those
findings may be replicated more widely in practice. This
is very much the case when considering societal or
health equity considerations.
8. Does the research consider equity as well as efficiency?
It is important that those studying the effectiveness
and cost-effectiveness of MBIs in different settings give
equity due consideration. Public health practitioners are
concerned with equity or inequalities in health and a
central goal has often been to improve the health of the
worst off in society. Health economists are increasingly
recognising the need to incorporate equity consider-
ations into their analysis (Weatherly et al. 2009). This
represents a departure from traditional economic analy-
sis which often implicitly has focused on an underlying
extra welfarist paradigm of health gain maximisation for
society (Culyer 2012). This represents a practical
operationalisation of a ‘trade-off’ between the goal of
efficiency (i.e. maximising an outcome such as health
gain) and goals of improving equity which may mean a
sacrifice of total potential health gains to society.
Worldwide, 20 % of people may experience mental
health problems during their lifetime. Mental health
disorders are estimated to account for a third of all years
lived with a disability (McDaid et al. 2008). Mental
health problems including suicide are linked with
socio-economic status (Department of Health 2009).
The UK Department of Health recommends that all
policies relating to health, including mental health,
should be assessed in terms of their potential impact on
inequalities in health, and where possible, favouring the
less well off (Department of Health 2009). It is important
that those designing studies of the effectiveness and cost-
effectiveness of MBIs consider that impacts on equity
has implications for the generalisability of results and is
key to the question of how to alleviate suffering associ-
ated with those facing multiple challenges of living in
socio-economically challenging circumstances.
As the number of trials of MBIs increase and their
settings become more varied, this aspect of economic
evaluation will come to the fore. This brings us to the
potential longer term impact of mindfulness-based train-
ing and the role of modelling in economic analysis.
9. Is economic modelling going to be useful in MBI
research?
Economic modelling is used by health economists,
particularly in the pharmacological industry, as an alter-
native to economic evaluation alongside a clinical trial
using patient level data, particularly where there is a
need to extrapolate beyond the length of follow-up
(Briggs et al. 2006). Modelling allows consideration of
uncertainty, particularly probabilistic decision analytic
modelling. It involves drawing estimates of costs and
estimates of effectiveness and the probabilities of
patients/individuals moving from one health state to
another, e.g. from episodes of wellness to relapse in
depression, in a Markov model (Briggs and Sculpher
1998).
However, in order to construct meaningful models,
sufficient data is required. There are at present very few
trials of MBIs that include an economic evaluation com-
ponent and, even when those underway now are pub-
lished, there will still be relatively few. There is a need to
consider that cost and outcome findings from an MBI in
one setting, e.g. cancer care, cannot necessarily be ex-
trapolated to a completely different setting, e.g. work-
place well-being. More trials and economic evaluations
are needed in a range of settings.
10. How should results be compared with the findings of
others studies, and used to advise service commissioners
and policy makers?
There is a growing body of evidence relating to
psychological therapies/psychosocial interventions to
support better mental health in schools, workplaces and
in health care settings (Knapp et al. 2011). MBIs have a
place amongst these psychological therapies both in
terms of treatment, prevention and promotion of resil-
ience.
What is now needed is a body of robust trial-based
evidence of effectiveness and cost-effectiveness to help
service commissioners and health and social care policy
makers, and in other contexts those responsible for edu-
cation policy and for improving social capital, to con-
sider the relative value for money of different psycho-
logical therapies, delivered in different settings, and
reaching different groups in society. This is where build-
ing cost-per-QALY estimates as well as condition-
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specific outcome measures provides an opportunity for
service commissioners and policy makers to compare
and rank interventions in terms of their value for money
(NICE 2008).
Discussion
While there is a growing body of evidence supporting effective-
ness of MBIs, more well-designed research evaluating cost-
effectiveness is now needed. Specific considerations towards
the design of a research trial or study are necessary in order to
provide a robust body of evidence for service commissioners
allocating scarce health care and social care resources. Many of
the challenges facing the economic evaluation of public health
interventions are relevant to mindfulness research. MBIs are
complex interventions and it is important that the depth and
breadth of effects are captured in economic analyses. Key meth-
odological considerations are required to counter factors such as
the need for a larger sample size as a result of a cluster
randomised design. Researchers should choose the method of
economic analysis most appropriate for the evaluating of MBIs
based on the perspective that costs and benefits are being mea-
sured. Where a threshold is relevant for a funding decision, as in
the case of NICE in the UK (NICE 2008), a cost-utility approach
which allows for cost-per-QALY estimates and comparisons
across interventions may be most appropriate. Cost–benefit anal-
ysis may be the most appropriate way for researchers interested
in mindfulness training in school or workplace settings, to cap-
ture the full economic benefits of improving well-being in a
broad sense. It may be that a cost–benefit approach is more
appropriate than a traditional cost-effectiveness approach focus-
sing on individuals’ assessment of their own health-related qual-
ity of life. Cost-consequence analysis is recommended by those
interested in the methodological challenges of public health
interventions as a solution to capturing a wide range of benefits,
e.g. to an individual, family, school or work place, or wider
society. It may be that cost-consequence analysis is most appro-
priate for capturing and illustrating the full range of wider ben-
efits of MBIs where monetary values are difficult to assign to
outcomes, as is necessary in cost–benefit analysis. A cost-utility
analysis or cost-effectiveness analysis, embedded in awider cost-
consequence analysis, maymeet commissioners need to inform a
decision rule, whilst acknowledging thewider range of outcomes
from a MBI. Public health practitioners focus on equity consid-
erations and inequalities in health. It is important that those
studying the effectiveness and cost-effectiveness of MBIs in
different settings also give these due consideration, particularly
with respect to making MBIs accessible to hard to reach groups
in society. This is relevant to the generalisability of results and to
the question of how to alleviate suffering associated with those
facing multiple challenges of living in socio-economically
challenging circumstances. While economic modelling may be
useful in mindfulness research, especially to extrapolate into the
longer term and to address uncertainty, more trials and data is
needed in order to populate the parameter estimates required in
economic models. The field of health economics has tended to
operate within the medical model paradigm of quantitative anal-
ysis. However, more recently health economists have begun to
acknowledge the potential contribution of qualitative research
methods in explaining measurable relationships (Coast 1999).
The health economist must be objective and dispassionate and
want to find out whether an intervention is effective and cost-
effective, regardless of whether the results of the trial or econom-
ic evaluation end up positive or negative. In our view, some
appreciation for the purpose, origins, delivery and potential range
of relevant costs and outcomes is essential to the design of a
robust economic evaluation of MBIs. Existing published health
economics literature of mindfulness interventions is beginning to
inform the body of economic evidence in this area. We encour-
age future trials of MBIs to build in a concurrent economic
evaluation in order to provide robust evidence to service
commissioners.
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